TESARO, Inc. , an oncology-focused biopharmaceutical company, today announced two niraparib presentations at the 2017 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer, March 12 to 15, 2017, in National Harbor, Maryland.
Category: Ovarian Cancer
NW Bio Reaches Agreement With Convertible Note Holders
As part of the consideration for these adjustments, Whitebox also will be receiving NW Bio common stock. The details of this cooperative arrangement are available in the 8-K filed by the Company this morning, which can be found on NW Bio’s website at www.nwbio.com Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both and Europe.
When robots ease the pain of women’s health issues
… better instruments so reduces complications. There is less blood loss and tissue damage, she says. Women have unique health issues that can hold them back in their fight for equality. A large majority of women develop fibroids by the time they reach …
Ovarian Cancer Diagnosis 2017: Frequent Screening Of CA125 Protein…
Women at heightened risk for ovarian cancer, such as those with inherited genetic mutations or a family history of the disease, are normally advised to have their ovaries and fallopian tubes removed once they have finished having children. While this remains the recommended medical advice, new research suggests that one day, surgery may not be the only cancer-prevention choice for high-risk women.
Becky Parsons has fought ovarian, womb and kidney cancer. Picture: Becky Parsons
… for me.” Every year on average about 24 people in 100,000 are diagnosed with ovarian cancer according to Public Health England – similar to the average across England. But in Oxfordshire the survival rates are higher than the average in England with …
She adopted daughters, found her love a ” then got a terminal diagnosis, and a miracle
Sarah Jorgensen and her family: daughters Isabella, 11, left; Vanessa, 10, right; and fiance Dan Norton. “You realize that relationships, at the end of the day, are what’s most important.
Maybe It’s Time To Stop Calling The GOP Obamacare Plan A ‘Replacement’
… of the repeated promises from President The Affordable Care Act has helped something like 20 million Americans get health insurance, primarily by expanding eligibility for Medicaid and making regulated, subsidized private insurance available to …
Working to beat the odds on a killer cancer
… Ovarian Cancer Australia board member Tracey Curro and CEO Jane Hill with Opposition Leader Bill Shorten and Shadow Health Minister Catherine King at morning tea during a visit to the Queen Victoria Women’s Centre in Melbourne last year. Picture: …
Boulder’s Clovis Oncology loses $349.1M in 2016
Boulder-based Clovis Oncology lost $349.1 million in 2016, or $9.01 per share, including a loss of $70.7 million, or $1.83 per share, in the fourth quarter ending Dec. 31, 2016.
Hormonal maintenance therapy can improve survival in women with rare ovarian, says study
Washington D.C. , Feb. 22 : Women with a rare type of epithelial ovarian or peritoneum cancer, can now take sigh of relief. A new study reveals that, hormonal maintenance therapy may significantly improve survival in women having low-grade serous carcinoma .
Olaparib maintenance therapy in patients with platinum-sensitive,…
Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly polymerase inhibitor therapy. Maintenance treatment with the oral poly polymerase inhibitor olaparib in Study 19 significantly improved progression-free survival in comparison with a placebo for patients with platinum-sensitive, relapsed serous ovarian cancer with a BRCA1/2 mutation , but an interim analysis revealed no statistically significant overall survival benefit.
Ovarian cancer: Australia’s ‘forgotten’ disease
Skip to navigation Skip to content Skip to footer View text version of this page Help using this website – Accessibility statement Join today and you can easily save your favourite articles, join in the conversation and comment, plus select which news your want direct to your inbox. When Ann Maree Mulders woke up still feeling unwell, she didn’t know 11 centimetres was about to change her life.
Analyzing copies of genes may offer new therapeutic approaches for ovarian cancer
… the pathway that stood out was autophagy — a natural process of cell death that helps maintain normal cellular health. Ovarian cancer cells use autophagy all of the time, but also lose several copies of autophagy genes resulting in a compromised …
Narell survives deadliest women’s cancer – twice
MISSION: Nowra’s Narell Whitehead has survived ovarian cancer twice and is out to raise awareness of the symptoms of risk factors of the disease. She recently hosted a fundraiser evening, raising more than $800 for Ovarian Cancer Australia.
When your wife refuses conventional cancer treatment
Method “public java.lang.String ” threw an exception when invoked on object See cause exception.
Recent Publication Highlights Proof-of-Concept Data Supporting the…
TUSTIN, Calif., Feb. 09, 2017 — Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced the publication of positive proof-of-concept data for a novel exosome-based cancer detection platform. Results of the study, conducted at University of Texas Southwestern Medical Center, showed researchers were able to distinguish between healthy subjects and patients with ovarian tumors based on the levels of exosomes containing phosphatidylserine found in their plasma.
3 Scorching Hot Biotech Stocks — Are They Buys?
Making a 70% return in only three months sounds pretty good. Three biotech stocks have done just that and more.
Defects in key gene spur breast and ovarian cancer growth, study shows
Defects in a key gene – long thought to drive cancer by turning off the protection afforded by the well-known BRCA genes – spur cancer growth on their own, according to a study led by researchers from NYU Langone Medical Center. The study gene, known as EMSY, has some of the same functions as BRCA1 and BRCA2, which are known to protect against breast and ovarian cancer when normal.
Old Cancer Drug Gets 1,000%-Plus Price Hike in Frugal U.K.
… isn’t the only medicine whose price has unexpectedly surged in one of the world’s most tightly-controlled markets for health spending. Melphalan, a chemotherapy in use for ovarian cancer since the 1950s, had a 315 percent cost increase in the same …
Futility
This past December was a hard month. Bigelow lab where I work, lost our director, Graham Shimmield to colon cancer, and we lost a trustee to cancer, I lost a cousin to ovarian cancer, and a colleague lost her mother, also to cancer.
Bisphosphonates for osteoporosis weakens bones: study
… news if you have osteoporosis – it could cause a broken hip. Osteoporosis is thinning of the bones, and it is a huge health concern. According to the National Osteoporosis Foundation, this silent epidemic affects roughly 10 million Americans, of …
Systematic drug sensitivity testing reveals synergistic growth…
Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Resistance to standard chemotherapy poses a major clinical problem in the treatment of ovarian cancer patients.
3 Biotechs Likely to Be Acquired in 2017
The year is still young, but we’ve already seen acquisitions of Ariad and CoLucid . Which biotechs could be scooped up next in 2017? Here’s why Clovis Oncology The number of big companies battling to acquire Medivationin 2016 shows that the oncology space is hot.
A New Drug Offers Hope for People With Deadly Cancers
A new drug is being developed that targets some aggressive cancers that are notoriously hard to cure. If the clinical trials that are underway continue to show promise, the drug may change the way some cancers are treated.
Teen Ruby McKinnon’s ovarian cancer: Overnight I looked 5 months pregnant
It was supposed to be like any other morning for Ruby McKinnon when she woke up at home after enjoying a night out with friends. Waking to a swollen, painful feeling in her abdomen, Ruby peeled back the blankets on her bed to reveal a sight she never expected to see develop overnight.
Neovacs to Collaborate with the Sunnybrook Research Inst.
Neovacs has formed a collaboration with Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada for preclinical development of Neovacs’ VEGF Kinoid, specifically to obtain the proof of concept for the treatment of colorectal and ovarian cancer. The Neovacs technology presents a new therapeutic opportunity for these types of cancers where the VEGF-A protein plays an important role in the vascularization of the tumor.
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy …
Primary advanced, unresectable ovarian cancer is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy.
Woman wants to share battle with ovarian cancer
And now, Newman-Overton is a woman in the middle of the fight of her life with stage four ovarian cancer, living a story . “Why is no one telling this?” Newman-Overton says.
Doxorubicin Market 2013 – 2024 – Research and Markets
… in demand for the drug. The technological advancement in te drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal …
FDA Grants Accelerated Approval to Rubraca for Advanced Ovarian Cancer
The FDA has granted accelerated approval to rucaparib to treat women with a certain type of ovarian cancer. Rucaparib is approved for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation , as identified by an FDA-approved companion diagnostic test.
Waltham’s Tesaro just got one step closer to winning FDA approval for its ovarian cancer drug
Waltham biotech Tesaro gained more than $400 million in market cap on Tuesday after the FDA indicated that it may approve the company’s ovarian cancer drug sooner than anticipated.
New Ovarian Cancer Drug Wins Speedy FDA Approval
U.S. health officials have approved a new option for some women battling ovarian cancer: a drug that targets a genetic mutation seen in a subset of hard-to-treat tumors. The Food and Drug Administration cleared the drug, Rubraca, from Clovis Oncology Inc. for women in advanced stages of the disease who have already tried at least two chemotherapy drugs.
Press release distribution, EDGAR filing, XBRL, regulatory filings
He had previously served a… )–Schnitzer Steel Industries, Inc. announced preliminary results for its first quarter of fiscal 2017 ended November 30, 2016. Schnitzer expects to repo… )–Total Safety Europe garandeert dat de beste technologieen toegankelijk zijn voor alle huurbehoeften van klanten.